Study may help explain racial disparities in prostate cancer

May 09, 2018

New research published in Molecular Oncology may help explain why African American men are at a higher risk of being diagnosed with prostate cancer and a higher risk of dying from the disease compared with European American men.

When investigators analyzed prostate cancer samples from patients, they found that a signaling molecule called interleukin-6 (IL6) is overexpressed in tumor-adjacent tissues in African-American men compared with European-American men.

Additional experiments revealed that IL6 inhibits expression of the p53 tumor suppressor protein, promotes self-renewal of cancer cells, and is associated with stem cell-like properties in prostate cancer cell lines.

"Our most recent research into the biological underpinnings for why African American men are more likely to be diagnosed with prostate cancer and die of the disease relative to other races or ethnicities has uncovered that IL6 is enriched in the tissue environment surrounding high-grade prostate cancer tumors from African American men," said senior author Dr. Aliccia Bollig-Fischer, of the Barbara Ann Karmanos Cancer Institute in Detroit. "Not only did we uncover evidence that IL6 inactivates the p53 tumor suppressor in this context, our research also revealed that IL6 from the cancer cell environment causes an increase of a protein variant called MBD2_v2. This fuels an expansion of aggressive cancer cells, known as prostate cancer stem cells, which are considered to be the source of therapy resistance and metastatic tumor growth."

In a follow-up study underway, Dr. Bollig-Fischer's laboratory team will gain a more complete understanding of this novel cancer cell signaling process activated by IL6 derived from the tumor environment. "Our goal is to identify opportunities to develop transformative, targeted therapies to overcome race disparities and improve outcomes for all men with aggressive prostate cancer," she said.
-end-


Wiley

Related Prostate Cancer Articles from Brightsurf:

Low risk of cancer spread on active surveillance for early prostate cancer
Men undergoing active surveillance for prostate cancer have very low rates - one percent or less - of cancer spread (metastases) or death from prostate cancer, according to a recent study published in the Journal of Urology®, an Official Journal of the American Urological Association (AUA).

ESMO 2020: Breast cancer drug set to transform prostate cancer treatment
A drug used to treat breast and ovarian cancer can extend the lives of some men with prostate cancer and should become a new standard treatment for the disease, concludes a major trial which is set to change clinical practice.

Major trial shows breast cancer drug can hit prostate cancer Achilles heel
A drug already licensed for the treatment of breast and ovarian cancers is more effective than targeted hormone therapy at keeping cancer in check in some men with advanced prostate cancer, a major clinical trial reports.

The Lancet: Prostate cancer study finds molecular imaging could transform management of patients with aggressive cancer
Results from a randomised controlled trial involving 300 prostate cancer patients find that a molecular imaging technique is more accurate than conventional medical imaging and recommends the scans be introduced into routine clinical practice.

Common genetic defect in prostate cancer inspires path to new anti-cancer drugs
Researchers found that, in prostate cancer, a mutation leading to the loss of one allele of a tumor suppressor gene known as PPP2R2A is enough to worsen a tumor caused by other mutations.

First prostate cancer therapy to target genes delays cancer progression
For the first time, prostate cancer has been treated based on the genetic makeup of the cancer, resulting in delayed disease progression, delayed time to pain progression, and potentially extending lives in patients with advanced, metastatic prostate cancer, reports a large phase 3 trial.

Men taking medications for enlarged prostate face delays in prostate cancer diagnosis
University of California San Diego School of Medicine researchers report that men treated with medications for benign prostatic hyperplasia (enlarged prostate) experienced a two-year delay in diagnosis of their prostate cancer and were twice as likely to have advanced disease upon diagnosis.

CNIO researchers confirm links between aggressive prostate cancer and hereditary breast cancer
The study has potential implications for families with members suffering from these types of tumours who are at an increased risk of developing cancer.

Distinguishing fatal prostate cancer from 'manageable' cancer now possible
Scientists at the University of York have found a way of distinguishing between fatal prostate cancer and manageable cancer, which could reduce unnecessary surgeries and radiotherapy.

Researchers find prostate cancer drug byproduct can fuel cancer cells
A genetic anomaly in certain men with prostate cancer may impact their response to common drugs used to treat the disease, according to new research at Cleveland Clinic.

Read More: Prostate Cancer News and Prostate Cancer Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.